CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 770 target
Drug / intervention
Adjuvant chemoradiotherapy +1 morecombination
Likely dose
Not stated in record
Key inclusion· 6
  • ✓Age 18-75 years
  • ✓Pathologically confirmed pancreatic ductal adenocarcinoma
  • ✓At least one high-risk feature: lymph node metastasis, R1/R2 resection, or lymphovascular invasion
  • ✓No prior chemotherapy after surgical resection
Key exclusion· 10
  • ✕Prior chemotherapy after surgical resection
  • ✕Other cancer within 5 years
  • ✕Disease progression on imaging
  • ✕ECOG ≥2

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06427447
NCT06427447Phase 3RecruitingOn TrackUpdated 16mo ago
CompareCT.gov

Adjuvant Chemoradiotherapy Versus Chemotherapy for Post-operative Pancreatic Cancer

Changhai Hospital·interventional·Posted May 23, 2024·Updated Feb 4, 2025

In Brief

A Phase 3 clinical trial evaluating Adjuvant chemoradiotherapy and Adjuvant chemotherapy for Pancreatic Cancer. Currently recruiting, targeting 770 participants across 1 site.

Detailed Summary

In this trial, we aim to compare the outcomes of adjuvant chemoradiotherapy with chemotherapy for patients with resected pancreatic cancer who are at high risk of disease progressions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesChina
Collaborators--

Timeline

Phase 3Recruiting
20252026202720282029
First PostedMay 23, 2024
Enrollment StartAug 6, 2024
Primary CompletionJun 30, 2028
Study CompletionJun 30, 2029
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 2.1 years agoPrimary completion in 2.0 years

Interventions

Adjuvant chemoradiotherapycombination

Upfront chemotherapy (gemcitabine plus capecitabine) followed chemoradiotherapy (radiotherapy with concurrent capecitabine)

Adjuvant chemotherapydrug

Chemotherapy (gemcitabine plus capecitabine)